Search results for "levodopa"

showing 10 items of 41 documents

Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

2021

AbstractAim of the study was to evaluate possible associations between cognitive dysfunctions and development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological evaluations were enrolled. Mild Cognitive Impairment (PD-MCI) was diagnosed according to MDS level II criteria. The following cognitive domains were evaluated: episodic memory, attention, executive function, visuo-spatial function and language. A domain was considered as impaired when the subject scored 2 standard deviation below normality cut-off values in at least one test for each domain. Levodopa equivalent dos…

Male0301 basic medicineDyskinesia Drug-InducedLevodopamedicine.medical_specialtyParkinson's diseaseScienceNeuropsychological TestsSeverity of Illness IndexArticleCohort StudiesLevodopaExecutive Function03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansAttentionCognitive DysfunctionLongitudinal StudiesAgedProportional Hazards ModelsLevodopa-induced dyskinesiaMultidisciplinarybusiness.industryQRNeuropsychologyParkinson DiseaseCognitionMiddle Agedmedicine.diseaseAged Attention Cognitive Dysfunction Cohort Studies Dyskinesia Drug-Induced Executive Function Female Humans Levodopa Longitudinal Studies Male Middle Aged Neuropsychological Tests Parkinson Disease Proportional Hazards Models Severity of Illness Index030104 developmental biologyNeurologyRisk factorsDyskinesiaCohortMedicineFemalemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugCohort studyScientific Reports
researchProduct

Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induct…

2002

Chronic administration of L-DOPA to MPTP-treated common marmosets induces marked dyskinesia while repeated administration of equivalent antiparkisonian doses of ropinirole and bromocriptine produces only mild involuntary movements. The occurrence of dyskinesia has been associated with an altered balance between the direct and indirect striatal output pathways. Using in situ hybridisation histochemistry, we now compare the effects of these drug treatments on striatal preproenkephalin-A (PPE-A) and adenosine A(2a) receptor mRNA expression as markers of the indirect pathway and striatal preprotachykinin (PPT) mRNA and preproenkephalin-B (PPE-B, prodynorphin) mRNA expression as markers of the d…

MaleDyskinesia Drug-Inducedmedicine.medical_specialtyIndolesCaudate nucleusStriatumIndirect pathway of movementAntiparkinson AgentsLevodopachemistry.chemical_compoundDopamine Uptake InhibitorsParkinsonian DisordersTachykininsInternal medicineNeural PathwaysmedicineAnimalsheterocyclic compoundsRNA MessengerProtein PrecursorsBromocriptineGeneral NeuroscienceMPTPPutamenNeuropeptidesReceptors Purinergic P1CallithrixEnkephalinsMazindoldopamine agonists peptide mRNAs L-DOPA 1-methyl-4-phenyl-1236-tetrahydropyridine primates dyskinesiaBromocriptinenervous system diseasesNeostriatumRopiniroleEndocrinologynervous systemchemistryDyskinesiaSettore BIO/14 - FarmacologiaFemalemedicine.symptommedicine.drugNeuroscience
researchProduct

The "gender factor" in wearing-off among patients with parkinson's disease: A post hoc analysis of DEEP study

2014

Background. The early detection of wearing-off in Parkinson disease (DEEP) observational study demonstrated that women with Parkinson’s disease (PD) carry an increased risk (80.1%) for wearing-off (WO). This post hoc analysis of DEEP study evaluates gender differences on WO and associated phenomena.Methods. Patients on dopaminergic treatment for ≥1 year were included in this multicenter observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well as the use of the 19-item wearing-off questionnaire (WOQ-19); WO was defined for scores ≥2. Post hoc analyses were conducted to investigate gender difference for demographic and clinical features …

MaleGenetics and Molecular Biology (all)medicine.medical_specialtyLevodopaParkinson's diseaseArticle SubjectCross-sectional studylcsh:MedicineDiseaseAged; Akathisia Drug-Induced; Antiparkinson Agents; Cross-Sectional Studies; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; Severity of Illness Index; Sex Factors; Medicine (all); Biochemistry Genetics and Molecular Biology (all); 2300lcsh:TechnologySeverity of Illness IndexBiochemistryGeneral Biochemistry Genetics and Molecular BiologyAntiparkinson AgentsLevodopaSex FactorsRisk FactorsInternal medicinePost-hoc analysisSeverity of illnessBIO/14 FarmacologiamedicineHumansProspective cohort studylcsh:ScienceGaitGeneral Environmental ScienceAgedAged; Akathisia Drug-Induced; Antiparkinson Agents; Cross-Sectional Studies; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; Severity of Illness Index; Sex Factors; Biochemistry Genetics and Molecular Biology (all); 2300; Medicine (all)2300business.industrylcsh:TMedicine (all)lcsh:RParkinson DiseaseGeneral Medicinemedicine.diseaseAkathisiaCross-Sectional StudiesDrug-InducedPhysical therapyObservational studylcsh:QFemalebusinessAkathisia Drug-InducedResearch Articlemedicine.drug
researchProduct

Reduction of Dopamine Level Enhances the Attractiveness of Male Drosophila to Other Males

2009

1932-6203 (Electronic); Dopamine is an important neuromodulator in animals and its roles in mammalian sexual behavior are extensively studied. Drosophila as a useful model system is widely used in many fields of biological studies. It has been reported that dopamine reduction can affect female receptivity in Drosophila and leave male-female courtship behavior unaffected. Here, we used genetic and pharmacological approaches to decrease the dopamine level in dopaminergic cells in Drosophila, and investigated the consequence of this manipulation on male homosexual courtship behavior. We find that reduction of dopamine level can induce Drosophila male-male courtship behavior, and that this beha…

MaleLevodopaanimal structuresDopaminemedia_common.quotation_subjectlcsh:MedicineNeuroscience/Neural HomeostasisCourtshipSexual Behavior Animal03 medical and health sciences0302 clinical medicineDopamineDopaminergic CellmedicineAnimalsHomosexuality Malelcsh:ScienceDrosophila030304 developmental biologymedia_common0303 health sciencesNeuroscience/Behavioral NeuroscienceMultidisciplinaryCourtship displaybiologyNeuroscience/Sensory Systemslcsh:RfungiCourtshipbiology.organism_classificationSex pheromonebehavior and behavior mechanismsDrosophilalcsh:QDrosophila melanogasterNeuroscience030217 neurology & neurosurgeryResearch Articlemedicine.drug
researchProduct

Impact of recommendations on the initial therapy of Parkinson’s disease: A population-based study in France

2011

International audience; Levodopa induces long-term motor complications in Parkinson's disease (PD). Therapeutic strategies that prevent motor complications are needed. Our aim was to evaluate the impact of recommendations of a French consensus conference published in 2000 on initial PD therapy. We identified 308 PD patients as part of a population-based study performed within the Mutualité Sociale Agricole in five French districts (2007). Neurologists confirmed PD diagnosis. We compared initial therapy in 102 patients treated before 12/31/2000 to that of 206 patients treated afterwards. Initial treatment was in agreement with the recommendations if dopamine agonists were used in patients <6…

MaleParkinson's diseaseEpidemiologyConsensus Development Conferences as TopicParkinson's diseaseMESH: Antiparkinson AgentsDiseaseAntiparkinson AgentsLevodopa0302 clinical medicineMESH: Practice Guidelines as TopicEpidemiology030212 general & internal medicinePractice Patterns Physicians'Initial therapyMESH: Dopamine AgonistsMESH: AgedMESH: Levodopaeducation.field_of_studyMESH: Middle AgedConsensus conferenceParkinson DiseaseMiddle Aged3. Good healthNeurologyDopamine AgonistsPractice Guidelines as TopicMESH: Guideline AdherenceFemaleFranceGuideline Adherencemedicine.drugmedicine.medical_specialtyLevodopaPopulationGuidelines03 medical and health sciencesInternal medicineMedical practicemedicineHumansMESH: Physician's Practice PatternseducationAgedMESH: HumansMESH: Consensus Development Conferences as Topicbusiness.industrymedicine.diseaseMESH: MaleMESH: FrancePopulation based study[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologiePhysical therapy[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeurology (clinical)Geriatrics and GerontologybusinessMESH: FemaleMESH: Parkinson Disease030217 neurology & neurosurgeryParkinsonism &amp; Related Disorders
researchProduct

Identification of the novel D297fsX318 PINK1 mutation and phenotype variation in a family with early-onset Parkinson's disease

2008

Herein we first describe a novel homozygous single nucleotide deletion in PINK1 exon 4 (889delG) which results in a loss of kinase domain on the PINK1 protein (D297fsX318). This mutation was identified in two brothers with early-onset Parkinson disease (EOPD) from a Sicilian consanguineous family. Of note, while one of the two patients developed mental deterioration and psychiatric problems, the other showed no cognitive decline. The present study supports the view that PINK1 is a pathogenic gene in some Italian families with EOPD and contributes to define the PINK1-associated phenotype. Herein we first describe a novel homozygous single nucleotide deletion in PINK1 exon 4 (889delG) which r…

MaleParkinson's diseaseGenotypeParkinson's diseaseMolecular Sequence DataPINK1DiseaseBiologyAntiparkinson AgentsLevodopaExonmedicineHumansAmino Acid SequenceAge of OnsetCognitive declineGeneAgedGeneticsGenotype–phenotype correlationPINK1Parkinson DiseaseExonsFamilial formmedicine.diseasePhenotypePedigreeSettore BIO/18 - GeneticaPhenotypeNeurologyMutationMutation (genetic algorithm)Settore MED/26 - NeurologiaNeurology (clinical)Geriatrics and GerontologyCognition DisordersProtein KinasesGene DeletionParkinsonism &amp; Related Disorders
researchProduct

Pallidotomy improves quality of life in selected parkinsonian patients: an Italian report.

1998

Pallidotomy has recently been reconfirmed as effective for otherwise intractable symptoms of Parkinson's disease. Nonetheless almost every aspect of its performance requires choices which are not fully established and may vary between centers. These include: 1) patient selection; 2) choice of imaging modality, 3) choice of anatomic landmarks for targeting the lesion, 4) choice of method for physiologic confirmation of location, 5) choice of lesion size and shape. We present two cases of pallidotomy procedures in Parkinsonian patients that in our knowledge are the first reported in Italy. Our experience and a careful review of the literature led to the following choices: 1) selection of Park…

MaleSettore MED/27 - NeurochirurgiaNeurosurgeryMiddle AgedGlobus PallidusMagnetic Resonance ImagingSeverity of Illness IndexLevodopaItalyPallidotomy Parkinson disease surgical treatment movement diseaseQuality of LifeHumansPostoperative PeriodParkinson Disease Secondary
researchProduct

Light and drug induced changes of epiphysial synaptic ribbons.

1976

In the present investigation experiments were carried out to determine whether the functionally obscure synaptic rebbons of mammalian pinealocytes can be affected by acute changes in environmental lighting and which chemical processes may be involved in their regulation. Experiments carried out in male guinea-pigs have shown that the amounts of synaptic ribbons are immediately affected by changes in the lighting pattern. Extension of the light period reduced the normally occurring increase, whereas extension of the dark period inhibited the normally occurring decrease in the amount of synaptic ribbons. Results following injections of a number of drugs known to influence pineal function (nor…

Malemedicine.medical_specialtyHistologyEnvironmental lightingReserpineSympathetic Nervous SystemLightPeriod (gene)Guinea PigsPropranololBiologyPineal GlandPathology and Forensic MedicinePinealocyteLevodopaPineal glandNorepinephrineInternal medicinemedicineAnimalsFenclonineCell BiologyReserpineDark periodPropranololβ receptormedicine.anatomical_structureEndocrinologySynapsesBiophysicssense organsmedicine.drugCell and tissue research
researchProduct

In patient’s with Parkinson disease, autonomic symptoms are frequent and associated with other non-motor symptoms

2015

Background: Autonomic symptoms and sleep disorders are common non-motor symptoms of Parkinson disease (PD), which are correlated with poor quality of life for patients. Purpose: To assess the frequency of autonomic symptoms in a consecutive series of PD patients and to correlate them with other motor and non-motor symptoms. Methods: All consecutive non-demented PD patients who underwent an extensive evaluation including Hoehn and Yahr staging, Unified Parkinson’s Disease Rating Scale, Beck’s Depression Inventory, Neuropsychiatric Inventory, PDQ-39 Scale, the Parkinson’s diseases Sleep Scale, the Epworth Sleepiness Scale and SCOPA-AUT scale were enrolled. Comorbidity has been also considered…

Malemedicine.medical_specialtyLevodopaNeurologyParkinson's diseaseDiseaseAutonomic symptomNon-motor symptomRating scaleInternal medicinemedicineHumansDepression (differential diagnoses)AgedEndocrine and Autonomic Systemsbusiness.industryEpworth Sleepiness ScaleParkinson DiseaseSleep disordersMiddle Agedmedicine.diseaseComorbidityCross-Sectional StudiesAutonomic Nervous System DiseasesParkinson’s diseaseFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessmedicine.drug
researchProduct

Chronic l-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats

2000

Abstract The effect of a unilateral 6-hydroxydopamine (6-OHDA) lesion of the left medial forebrain bundle and 3 weeks treatment with l -DOPA of normal and 6-OHDA lesioned rats on CB1r mRNA expression was investigated by in situ hybridization. A 6-OHDA lesion of nigrostriatal pathway alone, confirmed by the loss of nigral tyrosine hydroxylase mRNA, did not alter CB1r mRNA levels in the dopamine depleted striatum. Similarly, chronic l -DOPA treatment of normal rats had no effect on striatal CB1r mRNA expression. In contrast, chronic l -DOPA treatment of 6-OHDA-lesioned rats significantly increased CB1r mRNA expression in the denervated striatum. These results suggest that the CB1r activity ma…

Malemedicine.medical_specialtyLevodopaanimal structuresTyrosine 3-MonooxygenaseReceptors DrugDopamine Agents-DOPANigrostriatal pathwayStriatumBiologySubthalamic nucleusStriatumLevodopaLesionAdrenergic AgentsDopamineInternal medicinemedicineAnimalsRNA MessengerRats WistarOxidopamineReceptors CannabinoidMedial forebrain bundleHydroxydopamineTyrosine hydroxylaseGeneral NeuroscienceMedial Forebrain BundleParkinson DiseaseCorpus StriatumRatsmedicine.anatomical_structureEndocrinologynervous systemSettore BIO/14 - Farmacologiamedicine.symptomCannabinoid CB1 receptor mRNA6-Hydroxydopaminemedicine.drugNeuroscience Letters
researchProduct